Safety and immunogenicity of live, attenuated intranasal Bordetella pertussis vaccine (BPZE1) in healthy adults
| Autor: | C. Buddy Creech, Natalia Jimenez-Truque, Naomi Kown, Katherine Sokolow, Eric J. Brady, Sandra Yoder, Ken Solovay, Keith Rubin, Stephanie Noviello, Elizabeth Hensel, Semhal Selamawi, Adetunji Bakare, Mat Makowski, Kristina Lu |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Adult
Male Pertussis Vaccine General Veterinary General Immunology and Microbiology Whooping Cough Public Health Environmental and Occupational Health Tuberculin Vaccines Attenuated Bordetella pertussis Infectious Diseases Immunogenicity Vaccine Molecular Medicine Humans Female Administration Intranasal |
| Zdroj: | Vaccine. 40(47) |
| ISSN: | 1873-2518 |
| Popis: | BPZE1 is a live, attenuated pertussis vaccine derived from B. pertussis strain Tohama I modified by genetic removal or inactivation of 3 B. pertussis toxins: pertussis toxin, dermonecrotic toxin, and tracheal cytotoxin. This Phase 2a study evaluated the safety and immunogenicity of liquid or lyophilized BPZE1 vaccine administered intranasally by needleless tuberculin syringe or mucosal atomization device (VaxINatorFifty healthy male and non-pregnant female participants 18-49 years of age were enrolled. Participants were randomized 3:3:3:1 to a single lyophilized dose of 10Across all groups, 35/50 (70 %) experienced at least one local adverse event (AE) and 31/50 (62 %) experienced at least one systemic AE, with similar AE frequencies observed between the highest 10Lyophilized BPZE1 vaccine was well tolerated and immunogenic at the highest dose (10 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect